Quantrx Biomedical Corp (QTXB) financial statements (2022 and earlier)
Company profile
| Business Address |
P.O. BOX 4960 TUALATIN, OR 97062 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 55 | 130 | 322 | 460 | 1 | 61 | |||
| Cash and cash equivalents | 55 | 130 | 322 | 460 | 1 | 61 | |||
| Prepaid expense | 7 | 38 | 28 | 28 | 26 | ||||
| Deposits current assets | 50 | ||||||||
| Other undisclosed current assets | 403 | ||||||||
| Total current assets: | 55 | 137 | 360 | 891 | 29 | 137 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 1 | ||||||||
| Long-term investments and receivables | 222 | 500 | 170 | 200 | |||||
| Long-term investments | 222 | 500 | 170 | 200 | |||||
| Intangible assets, net (including goodwill) | (101) | 14 | 20 | ||||||
| Intangible assets, net (excluding goodwill) | (101) | 14 | 20 | ||||||
| Other undisclosed noncurrent assets | 101 | ||||||||
| Total noncurrent assets: | 222 | 500 | 184 | 221 | |||||
| TOTAL ASSETS: | 55 | 137 | 582 | 1,391 | 213 | 359 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 883 | 713 | 75 | 195 | 197 | 156 | |||
| Accounts payable | 16 | 48 | 49 | 168 | 161 | 122 | |||
| Accrued liabilities | 26 | 27 | 36 | 34 | |||||
| Interest and dividends payable | 866 | 665 | |||||||
| Debt | 1,388 | 1,388 | 1,871 | 1,825 | 1,095 | 814 | |||
| Due to related parties | 166 | 14 | 7 | 283 | |||||
| Other undisclosed current liabilities | 151 | 136 | 121 | 564 | 498 | ||||
| Total current liabilities: | 2,436 | 2,266 | 2,088 | 2,140 | 1,855 | 1,751 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 36 | 39 | |||||||
| Long-term debt, excluding current maturities | 36 | 39 | |||||||
| Total noncurrent liabilities: | 36 | 39 | |||||||
| Total liabilities: | 2,436 | 2,266 | 2,088 | 2,140 | 1,891 | 1,791 | |||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | (2,381) | (2,128) | (1,506) | (750) | (1,678) | (1,432) | |||
| Preferred stock | 62 | 62 | 62 | 167 | 167 | 167 | |||
| Common stock | 787 | 787 | 787 | 787 | 787 | 698 | |||
| Common stock, value, subscriptions | 9 | 9 | 9 | 9 | |||||
| Additional paid in capital | 48,876 | 48,876 | 48,876 | 48,792 | 48,740 | 48,678 | |||
| Accumulated deficit | (52,115) | (51,862) | (51,240) | (50,503) | (51,373) | (50,975) | |||
| Total stockholders' equity: | (2,381) | (2,128) | (1,506) | (750) | (1,678) | (1,432) | |||
| TOTAL LIABILITIES AND EQUITY: | 55 | 137 | 582 | 1,391 | 213 | 359 | |||
Income statement (P&L) ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1 | 0 | ||||||
| Revenue, net | ✕ | ✕ | ✕ | ✕ | 0 | |||
| Net investment income | 1 | |||||||
| Cost of revenue | (73) | (142) | (161) | (1,538) | (56) | (116) | ||
| Cost of goods and services sold | (11) | (84) | ||||||
| Gross profit: | (73) | (142) | (159) | (1,538) | (56) | (116) | ||
| Operating expenses | 12 | (60) | (75) | 1,373 | (83) | (243) | ||
| Other undisclosed operating loss | (1) | |||||||
| Operating loss: | (61) | (202) | (236) | (165) | (139) | (359) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (192) | (420) | (501) | 1,034 | (259) | |||
| Interest and debt expense | 25 | (198) | 100 | (2) | (2) | (2) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (228) | (820) | (637) | 867 | (400) | (361) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (25) | 198 | (100) | 2 | 2 | (107) | ||
| Net income (loss) available to common stockholders, diluted: | (253) | (622) | (737) | 869 | (398) | (468) | ||
Comprehensive Income ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (253) | (622) | (737) | 869 | (398) | (468) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (253) | (622) | (737) | 869 | (398) | (468) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.